Compare COOK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | CGEN |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.4M | 191.1M |
| IPO Year | 2021 | 2001 |
| Metric | COOK | CGEN |
|---|---|---|
| Price | $50.82 | $2.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $53.00 | $5.00 |
| AVG Volume (30 Days) | 26.5K | ★ 300.4K |
| Earning Date | 05-11-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $559,520,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.07 | $75.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $1.30 |
| 52 Week High | $86.59 | $3.24 |
| Indicator | COOK | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 47.71 |
| Support Level | $39.02 | $2.23 |
| Resistance Level | $77.25 | $2.54 |
| Average True Range (ATR) | 2.62 | 0.13 |
| MACD | -0.28 | -0.02 |
| Stochastic Oscillator | 30.17 | 6.32 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.